Innovestor Group, founded in 2014, is a Finnish venture capital firm headquartered in Helsinki. Innovestor’s approach combines venture capital funding with an online co-investment platform, enabling private investors to directly participate in funding rounds alongside the firm. This model has positioned Innovestor as a significant player in the Nordic venture capital landscape, fostering innovation and supporting the growth of early-stage companies.
During the last 6 months Innovestor has made several significant investments in both the energy technology and life sciences sectors. These investments reflect the company’s commitment to fostering innovation and advancing solutions in renewable energy optimization and medical research
Investment in Capalo AI: Advancing Energy Storage Optimization
In October 2024, Innovestor Group announced a strategic partnership with Capalo AI, a Finnish energy technology startup specializing in artificial intelligence-driven energy optimization. The investment is aimed at integrating 15 MW/60 MWh of behind-the-meter energy storage systems into Capalo AI’s Virtual Power Plant (VPP) platform.
Capalo AI’s technology enhances the profitability and efficiency of decentralized energy storage units by enabling them to participate in multiple energy markets. This optimization is crucial as renewable energy sources, such as wind and solar power, often introduce volatility into the energy grid. By utilizing AI-based predictive analytics, Capalo AI maximizes energy storage utilization, ensuring grid stability and increased revenue streams for asset owners.
This investment aligns with Innovestor’s long-term vision of supporting the transition to sustainable energy solutions. The backing from Innovestor will enable Capalo AI to accelerate its technology development, expand its market reach, and enhance its impact on the clean energy sector.
Life Sciences Investments: Supporting Finnish Biotech Innovations
Innovestor Group reinforced its commitment to healthcare advancements through its €90 million Life Science Fund by investing in three Finnish university spinouts: Polku Therapeutics, Kasvu Therapeutics, and Soihtu DTx. These startups focus on innovative treatments for neurological disorders, including Parkinson’s disease, Alzheimer’s, depression, and post-traumatic stress disorder (PTSD).
- Polku Therapeutics is developing targeted therapies to address neurodegenerative diseases by focusing on molecular mechanisms that slow disease progression.
- Kasvu Therapeutics is working on novel drug compounds aimed at treating mood and anxiety disorders, leveraging cutting-edge neuroscience research.
- Soihtu DTx specializes in digital therapeutics, combining artificial intelligence with medical interventions to provide personalized treatment solutions for psychiatric and neurological conditions.
These startups have collectively raised approximately €10 million, with strong international interest from biotech investors. Innovestor’s funding will support their research, clinical trials, and commercialization efforts, helping them bring groundbreaking treatments to market.
Polku Therapeutics and Kasvu Therapeutics both emerged from research conducted at the University of Helsinki, while Soihtu DTx is a spinout from Aalto University.
Photo: Polku Therapeutics
